This Boom-and-Bust Sector Surged to a Multiyear High

One group of stocks surged higher in January. And if the trend continues, we could see even bigger gains in the months ahead... [Stansberry Research Logo] Delivering World-Class Financial Research Since 1999 [DailyWealth] This Boom-and-Bust Sector Surged to a Multiyear High By Brett Eversole --------------------------------------------------------------- Last year was a great year for the broad market. But for certain sectors, it's a good thing 2023 is in the rearview mirror... Instead of soaring alongside the largest stocks, one corner of the market kept falling: biotech stocks. This notoriously boom-and-bust sector fell for most of 2023. But it surged at the end of the year. Biotech stocks hit a multiyear high in the process. That points to two possible outcomes. One could lead to potential double-digit upside this year... And if the trend continues, we might see even bigger gains in the months ahead. Let me explain... --------------------------------------------------------------- Recommended Links: # ['This Is How I'd Invest $1 Million']( "This is how I'd invest $1 million right now," says legendary investor Whitney Tilson. He's posting a new portfolio of stock picks for 2024. He isn't buying the Magnificent Seven... or putting an equal amount of cash into each. Instead, he's using the Monte Carlo Method to see which of 4,817 stocks could double your money. [Click here for the full details](. --------------------------------------------------------------- # [NEW: Urgent AI Update From Chaikin Analytics]( Last year, the Chaikin team recommended five AI-related stocks that have gone up an average of 30%... AND one of those stocks just crossed over 110%. If you missed out, don't worry – their Power Gauge system has just isolated a new opportunity in AI that could hand you double-digit (or higher) returns in a matter of weeks. [Click here to learn more](. --------------------------------------------------------------- Biotech stocks are known for their volatility. And given what these companies do, the booms and busts in biotech stocks make sense. These companies are at the cutting edge of medical research. They develop medications and therapies that can treat (or even eradicate) diseases. And their success hinges on whether an experimental product pans out. So investors tend to get overly excited – or overly pessimistic – about their prospects. This sector can surge to incredible gains. We saw that in the first year of the pandemic. But those bull runs are often followed by a collapse... which is what we've seen since. Recently, though, biotech stocks staged a breakout. They soared at the end of 2023. And they hit a multiyear high last month. Take a look... The rally was a major reversal for a sector that had been taking it on the chin. But biotech stocks could move much higher in the months ahead – even after a big breakout like this. To see it, I looked at every new 52-week high in biotech stocks. They've happened 19 other times since the data began in 1993. And they tend to lead to slight outperformance. Check it out... Similar setups saw six-month returns improve from 5.9% to 7.7%. And over a year, the typical gain improved from 12.1% to 13.8%. Now, this outperformance might not seem that impressive. That's because buying biotech stocks after new 52-week highs leads to more losing cases than you'd expect. Biotech stocks were higher a year after these breakouts just 58% of the time. So biotech stocks don't always keep soaring after these setups. But when they do, the returns get much better... In the winning trades, biotech stocks were typically up 17.5% over six months and 35.4% over a year. That means two scenarios are possible from here... Either biotech stocks will reverse back to the pain we saw for most of 2023, or they'll absolutely soar in the months ahead. We'll be watching this sector closely. If it rallies further from here, major outperformance is likely... So if prices keep rising, consider adding biotech to your portfolio. Good investing, Brett Eversole Further Reading Large-cap stocks staged a furious rally in the final months of 2023. But while all eyes were on the S&P 500 Index, another notable momentum shift took place in small caps. History tells us this trend reversal could mean double-digit gains are ahead for this "forgotten" space... [Read more here](. Despite gold's continued climb higher, many investors have given up on the metal. But that's a mistake. According to history, this rally is just getting started. Similar breakouts have led to solid upside over the next year... [Learn more here](. --------------------------------------------------------------- [Tell us what you think of this content]( [We value our subscribers' feedback. To help us improve your experience, we'd like to ask you a couple brief questions.]( [Click here to rate this e-mail]( You have received this e-mail as part of your subscription to DailyWealth. If you no longer want to receive e-mails from DailyWealth [click here](. Published by Stansberry Research. You’re receiving this e-mail at {EMAIL}. Stansberry Research welcomes comments or suggestions at feedback@stansberryresearch.com. This address is for feedback only. For questions about your account or to speak with customer service, call 888-261-2693 (U.S.) or 443-839-0986 (international) Monday-Friday, 9 a.m.-5 p.m. Eastern time. Or e-mail info@stansberryresearch.com. Please note: The law prohibits us from giving personalized financial advice. © 2024 Stansberry Research. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Stansberry Research, 1125 N Charles St, Baltimore, MD 21201 or [stansberryresearch.com](. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Stansberry Research does not recommend or endorse any brokers, dealers, or investment advisors. Stansberry Research forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Stansberry Research (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.